Dr. Reddy’s Laboratories Q4 results reported a 22% YoY jump in consolidated net profit to ₹1,594 crores. On a full-year basis, Dr. Reddy’s Laboratories’ net profit rose by 17% YoY to ₹5,654 crores in FY25.
On the Dr. Reddy’s Laboratories results date, i.e., on May 9, Dr. Reddy’s Laboratories share price closed at ₹1,155.90. In the last 5 years, the Dr. Reddy’s Laboratories share price has delivered more than 58% returns.
Dr. Reddy’s Laboratories Q4 Results: Revenue and EBITDA Margin
- In Dr. Reddy’s Laboratories quarterly results, revenue from operations rose 20% year-on-year to ₹8,506 crores, compared to ₹7,083 crores in Q4 FY24.
- On a sequential basis, revenue increased 2% over ₹8,358.6 crores reported in Q3 FY25. Net profit also grew 13% quarter-on-quarter from ₹1,413.3 crores.
- EBITDA for the quarter stood at ₹2,474.9 crores, representing 29% of revenue.
- EBITDA margin for the quarter expanded by 510 basis points from last year to 29.1%.
- A healthy balance sheet with a net cash surplus of ₹2,454 crores as on March 31, 2025.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Dr. Reddy’s Laboratories Q4 Results: Other Highlights
- In its global generics business, North America contributed ₹3,559 crores in revenue, a 9% year-on-year increase.
- Revenue from Europe rose 145% to ₹1,275 crores, which includes ₹597 crores from the newly acquired NRT business.
- The India business revenue grew 16% YoY to ₹1,305 crores.
- The Pharmaceutical Services & Active Ingredients (PSAI) segment reported revenue of ₹956.3 crores, up 16% year-on-year from ₹821.9 crores.
Dr. Reddy’s Laboratories Q4 Results: Management Commentary
Commenting on the results, co-chairman & MD, G V Prasad said, “We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business.
We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities.”
Dr. Reddy’s Laboratories Q4 Results: Dividend
Dr. Reddy’s Laboratories has declared a dividend of ₹8 per share (face value of ₹1 each) for the financial year ending March 31, 2025. The record date is fixed at July 10, 2025 (Thursday), while the payment date has not been declared yet.
So, open free Demat Account with SMC Global Securities to start your trading journey and stay updated with the Nifty 50 companies’ Q4 results.
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
